Drug Profile

Bevacizumab biosimilar - Zydus Cadila

Alternative Names: Bryxta; MAb3; ZRC-113; Zybev

Latest Information Update: 07 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Zydus Cadila
Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Non-small cell lung cancer

Most Recent Events

31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
26 Feb 2018 Ligand Pharmaceuticals, prior to February 2018, acquires the economic rights to the bevacizumab biosimilar programme that utilises the SUREtechnology platform
11 Aug 2017 Launched for Non-small cell lung cancer in India (Parenteral) before August 2017

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com